EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Wenjing Wang, Lisha Ye, Huihui Li, Weimin Mao, Xiaoling Xu iD

MedComm · 2024-11 · 5 (11)

DOI: 10.1002/mco2.782 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 15.10.2024. Verfasst von Wenjing Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Thoracic Oncology Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 244 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal cancer (EC) is identified as a predominant health threat worldwide, with its highest incidence and mortality rates reported in China. The complex molecular mechanisms underlying EC, coupled with the differential incidence of esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) across various regions, highlight the necessity for in‐depth research targeting molecular pathogenesis and innovative treatment strategies. Despite recent progress in targeted therapy and immunotherapy, challenges such as drug resistance and the lack of effective biomarkers for patient selection persist, impeding the optimization of therapeutic outcomes. Our review delves into the molecular pathology of EC, emphasizing genetic and epigenetic alterations, aberrant signaling pathways, tumor microenvironment factors, and the mechanisms of metastasis and immune evasion. We further scrutinize the current landscape of targeted therapies, including the roles of EGFR, HER2, and VEGFR, alongside the transformative impact of ICIs. The discussion extends to evaluating combination therapies, spotlighting the synergy between targeted and immune‐mediated treatments, and introduces the burgeoning domain of antibody–drug conjugates, bispecific antibodies, and multitarget‐directed ligands. This review lies in its holistic synthesis of EC's molecular underpinnings and therapeutic interventions, fused with an outlook on future directions including overcoming resistance mechanisms, biomarker discovery, and the potential of novel drug formulations.

Schlagwörter

Stichwörter der Autor:innen

combination therapiesesophageal cancermolecular pathogenesisresistance mechanismstarget therapy

Autor:innen und Institutionen

  • Department of Medical Thoracic Oncology Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang China.
  • Postgraduate Training Base Alliance Wenzhou Medical University Wenzhou Zhejiang China.
  • The Cancer Hospital of the University of Chinese Academy of Sciences, Institute of Basic Medicine and Cancer (IBMC) Chinese Academy of Sciences Hangzhou Zhejiang China.
  • Department of Radiation Oncology Shanghai Pulmonary Hospital, Tongji University School of Medicine Shanghai China.

ORCID-Profile: Xiaoling Xu

Förderung

  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Wang, W., Ye, L., Li, H., Mao, W., & Xu, X. (2024). Targeting esophageal carcinoma: molecular mechanisms and clinical studies. MedComm, 5(11). https://doi.org/10.1002/mco2.782

Vancouver

Wang W, Ye L, Li H, Mao W, Xu X. Targeting esophageal carcinoma: molecular mechanisms and clinical studies. MedComm. 2024;5(11). doi:10.1002/mco2.782

BibTeX
@article{Wang2024,
  author = {Wang, Wenjing and Ye, Lisha and Li, Huihui and Mao, Weimin and Xu, Xiaoling},
  title = {Targeting esophageal carcinoma: molecular mechanisms and clinical studies},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {11},
  doi = {10.1002/mco2.782}
}
Kostenlos starten →